Syndax publishes SAVE data on Revuforj combination in AML
The all-oral regimen showed 88% ORR and 71% CRc in relapsed/refractory AML.
Latest Syndax News & Updates
See the latest news and media coverage for Syndax. We track all announcements, press releases, and industry mentions in real time, all in one place.
Commercial-stage oncology company with approved targeted therapies
syndax.com- Headquarters
- New York, United States
- Company type
- Public company
- Number of employees
- 50–350
Last updated
Latest news about Syndax
In short: Syndax reported strong revenue growth, secured multiple FDA approvals for Revuforj and Niktimvo, and presented positive clinical data in 2025-2026.
Company announcements
Syndax highlights Revuforj clinical data at EHA 2026
Data show high response rates in multiple acute leukemia subtypes and settings, including real-world and frontline combinations.
Syndax announces $250M private placement of convertible senior notes
The 2.25% notes mature in 2031, and net proceeds of ~$243M will fund R&D, commercialization, and business development.
Syndax highlights Revuforj post-transplant data at ASCO 2026
Pooled analysis of 24 patients shows 90% 2-year overall survival, compared to historical 51%. Also presented PK data on drug interactions.
Media coverage
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar patients treated with revumenib monotherapy or combinations – – Ph 1 trial of revumenib...
Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98…
High response rates observed with the all-oral combination in a heavily pretreated population, including 88% (37/42) ORR, 71% (30/42) CRc, and 60% CR/CRh (25/42) ...
Syndax Pharmaceuticals (SNDX) Gets a Buy from Guggenheim
In a report released today, Bradley Canino from Guggenheim maintained a Buy rating on Syndax Pharmaceuticals, with a price target of $31.00. Deliver institutional-grade market...
Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes
Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Syndax Pharmaceuticals ( (SNDX)) just unveiled an update. On June 4...
Never miss news about Syndax
Track Syndax and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Syndax competitors & trending companies
Browse news for competitors to Syndax and other trending companies.
Kura Oncology
uniQure
Fujitsu
Kennedy Wilson
CervoMed
Eoptolink
Ligent
InnoLight
Nauticus Robotics
Regentis Biomaterials
Clearfield
IMC
Helical Fusion
BDO
PwC
Icertis
Deloitte
Execo
Grant Thornton
Aktis Oncology
GEODNET
Moxie
Onorato
Aloe Care
Tombot
CarePredict
Labrador
Joy for All
Intuition Robotics
temi
Rocket55
Kreativ HQ
NATIV3
Snap Agency
The Guerrilla